Title : Model-Based Design of a Decision Tree for Treating HER2+ Cancers Based on Genetic and Protein Biomarkers.

Pub. Date : 2015 Mar

PMID : 26225238






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Activating mutations in the PI3K and MAPK pathways (PIK3CA and KRAS), and expression of the HER3 ligand heregulin determined sensitivity to combinations of inhibitors against HER2 (lapatinib), HER3 (MM-111), AKT (MK-2206), and MEK (GSK-1120212; trametinib), in addition to the standard of care trastuzumab (Herceptin). Lapatinib erb-b2 receptor tyrosine kinase 3 Homo sapiens